Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Cosmos Pharmaceutical Corp. (3349:JPX), powered by AI.
Cosmos Pharmaceutical Corp. is currently trading at ¥6,150. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Cosmos Pharmaceutical Corp. on Alpha Lenz.
Cosmos Pharmaceutical Corp.'s P/E ratio is 15.7.
“Cosmos Pharmaceutical Corp. trades at a P/E of 15.7 (fair value) with solid ROE of 12.7%. 3Y revenue CAGR of 10.2% highlights clear growth momentum.”
Ask for details →Cosmos Pharmaceutical Corp. is a leading entity in the pharmaceutical retail sector, predominantly operating in Japan. The company's core purpose lies in the management and operation of drugstore chains, which provide a wide range of healthcare products and services to the public. In addition to its comprehensive selection of pharmaceuticals, Cosmos offers an array of consumer goods, including cosmetics, household items, and nutritional supplements. These product offerings cater to various consumer needs, enhancing the convenience and accessibility of essential goods. With a network of retail outlets strategically located across regions, Cosmos Pharmaceutical Corp. plays a significant role in fulfilling the everyday healthcare and lifestyle needs of consumers. The company’s business model emphasizes efficiency, customer satisfaction, and community engagement, contributing to its sustained market presence and influence in the competitive retail and healthcare sectors in Japan. Through these operations, Cosmos Pharmaceutical Corp. maintains its position as a pivotal player in the pharmaceutical and consumer retail market.
“Cosmos Pharmaceutical Corp. trades at a P/E of 15.7 (fair value) with solid ROE of 12.7%. 3Y revenue CAGR of 10.2% highlights clear growth momentum.”
Ask for details →Cosmos Pharmaceutical Corp. (ticker: 3349) is a company listed on JPX in the Healthcare sector (Pharmaceutical Retailers). It has approximately 5,709 employees. Market cap is $487.4B.
The current price is 6,150 with a P/E ratio of 15.73x and P/B of 1.89x.
ROE is 12.67% and operating margin is 3.99%. Annual revenue is $1.0T.